Premium
Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME‐VAC) in young adults
Author(s) -
BenYehuda Arie,
Joseph Aviva,
Zeira Evelyne,
EvenChen Simcha,
LouriaHayon Igal,
Babai Ilan,
ZakayRones Zichria,
Greenbaum Evgenia,
Barenholz Yechezkel,
Kedar Eli
Publication year - 2003
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.10345
Subject(s) - immunogenicity , medicine , seroconversion , virology , titer , immunization , hemagglutinin (influenza) , neuraminidase , influenza vaccine , vaccination , virus , immunology , immune system
Influenza and its complications account for substantial morbidity and mortality among young adults and especially among the elderly. In young adults, immunization provides 70–90% protection, while among the elderly the vaccine may be only 30–40% effective; hence the need for new, more immunogenic vaccines. We compared the safety and immunogenicity of a novel IL‐2‐supplemented liposomal influenza vaccine (designated INFLUSOME‐VAC) with that of a commercial subunit vaccine and a commercial split virion vaccine in young adults (mean age 28 years) in the winter of 1999–2000. Seventy‐three healthy young adults were randomly assigned to be vaccinated intramuscularly with the following: a commercial subunit vaccine (n = 17, group A), INFLUSOME‐VAC (n = 36, group B), and a commercial split virion vaccine (n = 20, group C). The three vaccines contained equal amounts of hemagglutinin (∼15 μg each) from the strains A/Sydney (H3N2), A/Beijing (H1N1), and B/Yamanashi. INFLUSOME‐VAC induced higher geometric mean HI titers and higher‐fold increases in HI titers against all three strains, compared with the two commercial vaccines. In addition, seroconversion rates for the A/Sydney and B/Yamanashi strains were significantly higher ( P < 0.05) compared with the split virion vaccine, and significantly higher for the three strains compared with the subunit vaccine (69–97% vs 35–65%, P ≤ 0.02). Moreover, the anti‐neuraminidase response was significantly greater ( P = 0.05) in group B vs group A. INFLUSOME‐VAC caused mild local pain at the injection site in a significantly higher proportion of the vaccinees (83%). Thus, INFLUSOME‐VAC is an immunogenic and safe vaccine in young adults. J. Med. Virol. 69:560–567, 2003. © 2003 Wiley‐Liss, Inc.